

2012



# GALIEN FORUM

TUESDAY OCTOBER 16, 2012

7:30 AM - 3:30 PM

ALEXANDRIA CENTER FOR LIFE SCIENCE -  
NEW YORK CITY

Apella Event Space at Alexandria Center  
450 East 29th Street, 2nd Floor  
(Between 1st Avenue And The East River)

PROGRAM

7:30 AM

**Registration**

## PLENARY SESSIONS

8:00 AM

### Welcome

**P. Roy Vagelos, M.D.**, *Committee Chairman, Prix Galien USA*

**Joel S. Marcus**, *Chairman, Chief Executive Officer & Founder, Alexandria Real Estate Equities, Inc. / Alexandria Venture Investments*

**Neil de Crescenzo**, *SVP and General Manager, Oracle Health Sciences*

8:15 AM

### Introduction

**Guido Rasi**, *Executive Director, European Medicines Agency*

**John Castellani**, *President & Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA)*

Moderator: **Andrew Jack**, *Financial Times*

9:15 AM

### Panel: "Looking Back, Moving Forward"

Moderator: **Roger Longman**

Panelists: **Fred Hassan, P. Roy Vagelos, M.D.**

A biopharma transformation is underway. Once an industry focusing on health conditions impacting tens of millions, it increasingly concentrates its research on disorders affecting far fewer patients with critical and costly conditions. Highly successful former CEOs discuss what needs to change about the kinds of organizations they used to run -- and the requirements for the leaders who will be running them tomorrow.

10:15 AM

**Coffee Break**

10:30 AM

## SIMULTANEOUS SESSIONS

### 1 PANEL I: Addressing Big Data Challenges in Genomics and Personalized Healthcare

**Moderator:**

**Kris Joshi, Ph.D.**, *Global Vice President, Healthcare, Oracle Health Sciences*

**Panelists:**

**Jean-Pierre A. Kocher, Ph.D.**, *Head, The*

*Bioinformatics Core (BIC) of the Mayo Clinic*

**Martin Leach**, *Chief Information Officer, Broad Institute, MIT and Harvard*

**Nadeem Sarwar, MRPharmS Ph.D.**, *Senior Director – Head, Population Research & Head, Cardiovascular Genetics, Pfizer*

**Scot Stevens**, *Chief Information Officer, UPMC CancerCenter & UPCI, Director*

*Personalized Medicine Technology, UPMC*

As the cost of genome sequencing has declined dramatically during the past years, a consumer driven genomics revolution is around the corner. This will have a profound impact on the prospects for personalized healthcare. However, gains in genome sequencing are only part of the journey toward personalized healthcare. The panel is in formation. This session will discuss and debate the opportunities and challenges in the quest for personalized healthcare.

**Topics include:**

- > How will the equation between the cost of genome sequencing and the cost of analysis be balanced?
- > How long will it be before genomic analysis is available to clinicians?
- > How will the patient manage his/her own genomic information?
- > What role will access to large public reference datasets play in accelerating personalized healthcare initiatives?.

### 2 PANEL II: Infectious Diseases: A Global Healthcare Challenge

**Moderator:**

**Maria Freire, Ph.D.**, *President, Albert and Mary Lasker Foundation*

**Panelists:**

**Alice Dautry, Ph.D.**, *Director*

*General, Institut Pasteur*

**Julie Gerberding, M.D., MPH**, *President, Merck Vaccines, Merck & Co., Inc.; Former Director, Centers for*

*Disease Control and Prevention (CDC)*

**Margaret Hamburg, M.D.**, *Commissioner, U.S. Food and*

*Drug Administration*

**Lynn Marks, M.D.**, *Senior Vice President,*

*Medicines Development Center for Infectious*

*Diseases, GlaxoSmithKline plc*

Esteemed panelists will discuss the challenges and opportunities facing the field of emerging infectious diseases from a global perspective, identifying the field's most critical issues while discussing future strategies to accelerate the development of therapies to treat, diagnose and prevent infectious diseases ranging from HIV/AIDS, TB, Hepatitis B and C, Malaria, drug resistant Staph, and other important and neglected diseases.

### 3 PANEL III: Alzheimer's Innovation and the White House 2025 Mandate: What Will it Take to Find a Treatment?

**Moderator:**

**Michael Rosenblatt, M.D.**, *Executive Vice President and Chief Medical Officer, Merck*

**Panelists:**

**Meryl Comer**, *President, Geoffrey*

*Beene Foundation Alzheimer's Initiative*

**Stephen Hume, M.D.**, *a leading clinician and a patient with early onset Alzheimer's disease*

**Russell Katz, M.D.**, *Director, Division*

*of Neurology Products, Center*

*for Drug Evaluation and Research,*

*U.S. Food and Drug Administration*

**William Potter, M.D., Ph.D.**, *Senior Advisor,*

*National Institute of Mental Health*

**Dennis Selkoe, M.D.**, *Co-Director,*

*Center for Neurological Diseases, Brigham and*

*Women's Hospital, and Vincent and Stella*

*Coates Professor of Neurologic Diseases,*

*Harvard Medical School*

**William Thies, M.D.**, *Chief Medical*

*and Scientific Officer, Alzheimer's Association*

A conversation with government, industry and advocacy leaders on Alzheimer's innovation and the White House 2025 mandate to develop an effective medicine.

12:00 PM

Lunch break

## PLENARY SESSION

12:30 PM

### Ethics of Innovation

**Moderator:**

**Professor Elie Wiesel**, *Author and Peace Nobel Prize Laureate*

**Panelists:**

**Margaret Hamburg, M.D.**, *Commissioner, U.S. Food and Drug Administration*

**Guido Rasi**, *Executive Director, European Medicines Agency*

Innovation in biomedicines is essential to maintaining progress in global public health. This panel will review key issues in the science and policy of innovation, including the roles of government, the private sector, academia and other stakeholders in fostering new medical advances; prioritizing current and future areas of unmet medical need; establishing an appropriate regulatory balance between drug risk and benefit; promoting access, affordability and the human right to health; and defining our collective moral responsibilities to the patient, through the ethical conduct of human clinical trials, safe use of new health technologies, and preventing the misrepresentation of science for political or ideological means.

2:00 PM - 3:30 PM **4** PANEL

2:00 PM

**The changing face of Chinese healthcare**

Moderator:

**Kimberly Ha**, *Global Editor, Biopharm Insight*

Panelists:

**Douglas Andrews**, *CEO and Director at Stravencon***Les Funtleyder**, *fund manager, Polliwog***R.T. (Terry) Hisey**, *Vice Chairman & US Life Sciences Leader, Deloitte LLP***Joanne Jiang**, *co-founder, Fountain Medical Development***William Kridel**, *partner, Ferghana Partners***Anthony Sun**, *partner, Aisling Capital*

This session will discuss and debate the opportunities and challenges with investing in the Chinese healthcare market. How do companies navigate doing business in this high growth, emerging market?

Discussion topics:

What are the major trends and issues companies need to be aware of before doing business in China?

What is the SFDA product approval process in China?

What to look for when selecting a CRO partner?

Current trends in the Chinese healthcare market?

**5** PANEL**Art and Science: From Anatomy to Genetics**Moderator: **Eliane Strosberg, MD., PhD.\***

This presentation will focus on the intersections between art and medicine, from anatomy to genetics.

The dialogue between Art and Science has powerfully shaped both endeavors since antiquity and is increasingly recognized as a major driving force of future education at the highest level.

*\* Eliane Strosberg holds an MD and a PhD from Brussels University and was a Research Fellow at Harvard.*

*She held several international management positions in American consulting firms for the chemical and pharmaceutical industries.*

*In addition, she received training in art history at the Brussels Free University and worked in the research laboratory of the Boston Museum of Fine Arts. She has devoted a lot of time to research the connections between Art and Science which resulted in a book first published by UNESCO that evolved into a broad cultural educational program. It was translated in several languages and was published in the USA by Abbeville, Inc.*

*Her second book, Human Expressionism, tackles the question of art and religion. The book served as the catalogue for a widely acclaimed exhibition in France and was selected by the Art Books Fair at the Pompidou Center in Paris. The updated American edition was first presented at the NY Public Library.*

**RSVP:** Dress Code: Business Attire.  
 RSVP on our website: [forum.galienfoundation.org](http://forum.galienfoundation.org)

The Galien Foundation  
 60 Broad Street, Suite 3502 KVB  
 New York, NY 10004  
 Tel 212 685 1592  
[www.galienfoundation.org](http://www.galienfoundation.org)